-
公开(公告)号:US07803823B2
公开(公告)日:2010-09-28
申请号:US11742741
申请日:2007-05-01
申请人: Christopher John Love , Guy Rosalia Eugeen Van Lommen , Julien Georges Pierre-Olivier Doyon , Jean-Pierre André Marc Bongartz , Marcel Jozef Maria Van der Aa , Robert Jozef Maria Hendrickx , Peter Jacobus Johannes Antonius Buijnsters , Ludwig Paul Cooymans , Nele Vandermaesen , Erwin Coesemans , Gustaaf Maria Boeckx
发明人: Christopher John Love , Guy Rosalia Eugeen Van Lommen , Julien Georges Pierre-Olivier Doyon , Jean-Pierre André Marc Bongartz , Marcel Jozef Maria Van der Aa , Robert Jozef Maria Hendrickx , Peter Jacobus Johannes Antonius Buijnsters , Ludwig Paul Cooymans , Nele Vandermaesen , Erwin Coesemans , Gustaaf Maria Boeckx
IPC分类号: A61K31/425 , C07D277/20
CPC分类号: C07D417/04 , C07D277/42 , C07D471/04
摘要: This invention concerns the use of a compound of formula (I′) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C1-6alkyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; aminocarbonyl; C1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with C1-4alkyl substituted piperidinyl, mono- or di(C1-6alkyl)amino, aminocarbonyl, mono- or di(C1-6alkyl)aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; polyhaloC1-4alkyl; cyano; amino; mono- or di(C1-6alkyl)aminocarbonyl; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; aminoS(═O)2—; mono- or di(C1-6alkyl)aminoS(═O)2; —C(═N—Rx)NRyRz; Q is optionally substituted C3-6cycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-α and/or IL-12.
摘要翻译: 本发明涉及式(I')化合物的N-氧化物,药学上可接受的加成盐,季胺及其立体化学异构体形式的用途,其中Z为卤素; C 1-6烷基; C 1-6烷基羰基; C 1-6烷氧基羰基; 氨基羰基; 被羟基,羧基,氰基,氨基,被哌啶取代的氨基,被C 1-4烷基取代的哌啶基取代的氨基,单或二(C 1-6烷基)氨基,氨基羰基,一或二(C 1-6烷基)氨基羰基 C 1-6烷氧基羰基,C 1-6烷氧基,哌啶基,哌嗪基,吗啉基,硫代吗啉基; 多卤代C 1-4烷基; 氰基; 氨基; 单或二(C 1-6烷基)氨基羰基; C 1-6烷氧基羰基; C 1-6烷基羰基氧基; 氨基S(= O)2-; 单或二(C 1-6烷基)氨基S(= O)2; -C(= N-Rx)NR y R z; Q是任选取代的C 3-6环烷基,苯基,吡啶基,嘧啶基,吡嗪基,哒嗪基,苯并噻唑基,苯并恶唑基,苯并咪唑基,吲唑基或咪唑并吡啶基,或Q是式L的基团是任选取代的苯基或任选取代的单环5或6- 元部分饱和或芳族杂环或双环部分饱和或芳族杂环; 芳基是任选取代的苯基; 用于制备用于预防或治疗通过TNF-α和/或IL-12介导的炎症和/或自身免疫疾病的药物。
-
公开(公告)号:US07232838B2
公开(公告)日:2007-06-19
申请号:US10486819
申请日:2002-08-09
申请人: Christopher John Love , Guy Rosalia Eugeen Van Lommen , Julien Georges Pierre-Olivier Doyon , Jean-Pierre André Marc Bongartz , Marcel Jozef Maria Van der AA , Robert Jozef Maria Hendrickx , Peter Jacobus Johannes Antonius Buijnsters , Ludwig Paul Cooymans , Nele Vandermaesen , Erwin Coesemans , Gustaaf Maria Boeckx
发明人: Christopher John Love , Guy Rosalia Eugeen Van Lommen , Julien Georges Pierre-Olivier Doyon , Jean-Pierre André Marc Bongartz , Marcel Jozef Maria Van der AA , Robert Jozef Maria Hendrickx , Peter Jacobus Johannes Antonius Buijnsters , Ludwig Paul Cooymans , Nele Vandermaesen , Erwin Coesemans , Gustaaf Maria Boeckx
IPC分类号: A61K31/425 , C07D277/00 , C07D277/20
CPC分类号: C07D417/04 , C07D277/42 , C07D471/04
摘要: This invention concerns the use of a compound of formula (I′), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C1-6alkyl; C1-6alkylcarbonyl; C1-6alkyloxy -carbonyl; aminocarbonyl; C1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with C1-4alkyl substituted piperidinyl, mono- or di(C1-6alkyl)amino, aminocarbonyl, mono- or di(C1-6alkyl)aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; polyhaloC1-4alkyl; cyano; amino; mono- or di(C1-6alkyl)aminocarbonyl; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; aminoS(═O)2—; mono- or di(C1-6alkyl)aminoS(═O)2; —C(═N—Rx)NRyRz; Q is optionally substituted C3-6cycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula (b-1), (b-2), or (b-3), L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-α and/or IL-12
摘要翻译: 本发明涉及式(I')化合物,N-氧化物,药学上可接受的加成盐,季胺及其立体化学异构体形式的用途,其中Z是卤素; C 1-6烷基; C 1-6烷基羰基; C 1-6烷氧基羰基; 氨基羰基; 用羟基,羧基,氰基,氨基,被哌啶取代的氨基,被C 1-4烷基取代的哌啶基取代的氨基,单或二( C 1-6烷基)氨基,氨基羰基,一或二(C 1-6烷基)氨基羰基,C 1-6烷氧基羰基, C 1-6烷基氧基,哌啶基,哌嗪基,吗啉基,硫代吗啉基; 多卤代1-4烷基; 氰基; 氨基; 单或二(C 1-6烷基)氨基羰基; C 1-6烷氧基羰基; C 1-6烷基羰基氧基; 氨基-S(-O)2 - ; 单或二(C 1-6烷基)氨基S(-O)2; -C(-N-R x X)NR z R z Z; Q为任选取代的C 3-6环烷基,苯基,吡啶基,嘧啶基,吡嗪基,哒嗪基,苯并噻唑基,苯并恶唑基,苯并咪唑基,吲唑基或咪唑并吡啶基,或Q为式(b-1) ,(b-2)或(b-3)中,L是任选取代的苯基或任选取代的单环5或6元部分饱和或芳族杂环或双环部分饱和或芳族杂环; 芳基是任选取代的苯基; 用于制备用于预防或治疗通过TNF-α和/或IL-12介导的炎症和/或自身免疫疾病的药物
-
公开(公告)号:US08981094B2
公开(公告)日:2015-03-17
申请号:US12663013
申请日:2008-06-06
申请人: Jean-Pierre André Marc Bongartz , Joannes Theodorus Maria Linders , Lieven Meerpoel , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Mirielle Braeken , Christophe Francis Robert Nestor Buyck , Monique Jenny Marie Berwaer , Katharina Antonia Germania J. M. De Waepenaert , Peter Walter Maria Roevens , Gustaaf Maria Boeckx , Petr Vladimirivich Davidenko
发明人: Jean-Pierre André Marc Bongartz , Joannes Theodorus Maria Linders , Lieven Meerpoel , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Mirielle Braeken , Christophe Francis Robert Nestor Buyck , Monique Jenny Marie Berwaer , Katharina Antonia Germania J. M. De Waepenaert , Peter Walter Maria Roevens , Gustaaf Maria Boeckx , Petr Vladimirivich Davidenko
IPC分类号: C07D211/00 , C07D241/04 , C07D295/00 , C07D401/00 , C07D403/00 , C07D295/205 , C07D207/09 , C07D211/26 , C07D211/38 , C07D213/40 , C07D213/56 , C07D213/61 , C07D213/75 , C07D233/18 , C07D295/192 , C07D295/21 , C07D295/215 , C07D295/24 , C07D295/26 , C07D307/52 , C07D307/79 , C07D309/04 , C07D317/58 , C07D333/24
CPC分类号: C07D295/205 , C07D207/09 , C07D211/26 , C07D211/38 , C07D213/40 , C07D213/56 , C07D213/61 , C07D213/75 , C07D233/18 , C07D295/192 , C07D295/21 , C07D295/215 , C07D295/24 , C07D295/26 , C07D307/52 , C07D307/79 , C07D309/04 , C07D317/58 , C07D333/24
摘要: The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —C(═O)—; —O—C(═O)—; C(═O)—C(═O)—; —NRx—C(═O)—; —Z1—C(O)—; —Z1—NRx—C(═O)—; —C(═O)—Z1—; —NRx—C(═O)—Z1—; —S(═O)p-; —C(═S)—; —NRx—C(═S)—; —Z1—C(═S)—; —Z1—NRx—C(═S)—; —C(═S)—Z1-; —NRx—C(═S)—Z—; Y represents NRx—C(=0)-Z2—; —NRx—C(=0)-Z2—NRy—; —NRx—C(=0)-Z2—NRy—C(=0)-; —NRx—C(=0)-Z2—NRy—C(=0)-O—; —NRx—C(=0)-Z2-0-; —NRx—C(=0)-Z2-0-C(=0)-; —NRx—C(=0)-Z2—C(=0)-; —NRx—C(=0)-Z2—C(=0)-; —NRx—C(=0)-0-Z2—C(=0)-; —NRx—C(=0)-0-Z2—C(=0)-0-; —NRx—C(═O)—O—Z2—O—C(═O)—; —NRx—C(═O)—Z2—C(═O)—NRy—; —NRx—C(═O)—Z2—NRy—C(=0)-NRy—; —C(═O)—Z2—; —C(═O)—Z2—O—; —C(=0)-NRx—Z2—; —C(=0)-NRx—Z2-0-; —C(=0)-NRx—Z2—C(=0)-0-; —C(=0)-NRx—Z2-0-C(=0)-; —C(=0)-NRx—Z2—NRy—; —C(=0)-NRx—Z2—NRy—C(=0)-; —C(=0)-NRx—Z2—NRy—C(=0)-0-; R1 represents C1-12alkyl optionally substituted with cyano, C1-4alkyloxy, C1-4alkyl-oxyC1-4alkyloxy, C3-6Cycloalkyl or aryl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; adamantanyl; aryl1; aryl1C1-6alkyl; Het1; or Het1C1-6alkyl; provided that when Y represents —NRX—C(═O)—Z2—; —NRx—C(=0)-Z2—NRy; —NRX—C(═O)—Z2—C(═O)—NRy—; —C(═O)—Z2—; —NRx—C(=0)-Z2—NRy—C(=0)-NRy—; —C(═O)—NRX—Z2—; —C(═O)—NRX—O—Z2—; or —C(=0)-NRx—Z2—NRy—; then R1 may also represent hydrogen; R2 represents hydrogen, C1-12alkyl, C2-6alkenyl or R3; provided that if X represents —O—C(═O)—; the R2 represents R3; and provided that (A) is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
-
公开(公告)号:US20070249691A1
公开(公告)日:2007-10-25
申请号:US11569268
申请日:2005-05-24
申请人: Gustaaf Boeckx , Guy Rosalia Eugeen Van Lommen , Julien Georges Pierre-Olivier Doyon , Erwin Coesemans
发明人: Gustaaf Boeckx , Guy Rosalia Eugeen Van Lommen , Julien Georges Pierre-Olivier Doyon , Erwin Coesemans
IPC分类号: A61K31/4164 , A61K31/421 , A61K31/4245 , A61K31/426 , A61P29/00 , C07D233/84 , C07D261/06 , C07D271/10 , C07D277/18
CPC分类号: C07C211/29 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/501 , A61K31/502 , C07D233/84 , C07D233/88 , C07D401/04 , C07D401/06 , C07D403/06 , C07D409/04 , C07D409/06 , C07D413/04 , C07D413/06 , C07D417/06
摘要: The present invention relates to a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine, a polymorphic form or a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxyC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 represents hydrogen, cyano, optionally substituted C1-6alkyl, C(═O)—O—R5, C(═O)—NR6aR6b, C(═S)—NR6aR6b, S(═O)2—NR6aR6b or C(═O)—R7; R4 represents hydrogen or C1-6alkyl; n is 1, 2, 3, 4 or 5; Z represents a cyclic ring system. The invention also relates to processes for preparing the compounds of formula (I), their use as CCR2 antagonists and pharmaceutical compositions comprising them.
摘要翻译: 本发明涉及式(I)化合物的N-氧化物,药学上可接受的加成盐,季胺,多晶型或其立体化学异构形式,其中R 1表示氢, C 1-6烷基,C 3-7环烷基,C 1-6烷氧基C 1-6烷基, 二(C 1-6烷基)氨基C 1-6烷基,芳基或杂芳基; 每个R 2独立地代表卤素,C 1-6烷基,C 1-6烷氧基,C 1-6 烷硫基,多卤C 1-6烷基,多卤C 1-6烷氧基,氰基,氨基羰基,氨基,单或二(C 1-4) 烷基)氨基,硝基,芳基或芳氧基; R 3表示氢,氰基,任选取代的C 1-6烷基,C(-O)-OR 5,C(O) -NR 6 C 6b,C(-S)-NR 6a R 6b,S(-O) C 1 -C 6烷基或C(-O)-R 7; R 4表示氢或C 1-6烷基; n为1,2,3,4或5; Z表示环状体系。 本发明还涉及制备式(I)化合物的方法,它们作为CCR2拮抗剂的用途和包含它们的药物组合物。
-
公开(公告)号:US07511068B2
公开(公告)日:2009-03-31
申请号:US10544569
申请日:2004-01-30
申请人: Guy Rosalia Eugeen Van Lommen , Julien Georges Pierre-Olivier Doyon , Jean Pierre Frans Van Wauwe , Marina Lucie Louise Cools , Erwin Coesemans
发明人: Guy Rosalia Eugeen Van Lommen , Julien Georges Pierre-Olivier Doyon , Jean Pierre Frans Van Wauwe , Marina Lucie Louise Cools , Erwin Coesemans
IPC分类号: A61K31/4164 , C07D233/04
CPC分类号: A61K31/4174 , A61K31/4178 , A61K31/5025 , C07D233/84 , C07D233/90 , C07D263/44 , C07D409/06 , C07D487/04
摘要: The present invention relates to a compound of formula (I) having CCR2 receptor antagonistic properties, particularly anti-inflammatory properties.
摘要翻译: 本发明涉及具有CCR2受体拮抗性质,特别是抗炎性质的式(I)化合物。
-
公开(公告)号:US08946228B2
公开(公告)日:2015-02-03
申请号:US12663011
申请日:2008-06-06
申请人: Jean-Pierre André Marc Bongartz , Joannes Theodorus Maria Linders , Lieven Meerpoel , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Mirielle Braeken , Christophe Francis Robert Nestor Buyck , Monique Jenny Marie Berwaer , Katharina Antonia Germania J. M. De Waepenaert , Peter Walter Maria Roevens , Petr Vladimirivich Davidenko
发明人: Jean-Pierre André Marc Bongartz , Joannes Theodorus Maria Linders , Lieven Meerpoel , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Mirielle Braeken , Christophe Francis Robert Nestor Buyck , Monique Jenny Marie Berwaer , Katharina Antonia Germania J. M. De Waepenaert , Peter Walter Maria Roevens , Petr Vladimirivich Davidenko
IPC分类号: A61K31/4965 , C07D241/04 , C07D295/00 , A61K31/451 , A61K31/495 , C07D207/323 , C07D211/26 , C07D231/12 , C07D233/54 , C07D233/64 , C07D235/18 , C07D249/08 , C07D257/04 , C07D263/34 , C07D277/56 , C07D279/02 , C07D279/12 , C07D295/20 , C07D307/54 , C07D319/18 , C07D401/12 , C07D417/12 , C07D417/14
CPC分类号: A61K31/4523 , A61K31/451 , A61K31/454 , A61K31/495 , A61K31/496 , C07D207/277 , C07D207/323 , C07D211/26 , C07D211/60 , C07D231/12 , C07D233/54 , C07D233/64 , C07D235/18 , C07D249/08 , C07D257/04 , C07D263/34 , C07D277/56 , C07D279/02 , C07D279/12 , C07D295/20 , C07D295/205 , C07D295/21 , C07D295/215 , C07D307/54 , C07D319/18 , C07D401/12 , C07D417/12 , C07D417/14
摘要: The invention relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine, as a DGAT inhibitor, of said compounds.
摘要翻译: 本发明涉及式(I)的DGAT抑制剂,包括其任何立体化学异构形式,其N-氧化物,其药学上可接受的盐或其溶剂合物,以及制备这些化合物的方法,包含所述化合物的药物组合物 作为所述化合物作为DGAT抑制剂的药物使用。
-
公开(公告)号:US08633197B2
公开(公告)日:2014-01-21
申请号:US12663007
申请日:2008-06-05
申请人: Jean-Pierre André Marc Bongartz , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Christophe Francis Robert Nestor Buyck
发明人: Jean-Pierre André Marc Bongartz , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Christophe Francis Robert Nestor Buyck
IPC分类号: A61K31/4965 , C07D241/04 , C07D295/00
CPC分类号: C07D295/215 , C07D231/12
摘要: The invention relates to a DGAT inhibitor of formula including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
摘要翻译: 本发明涉及一种DGAT抑制剂,其包括其任何立体化学异构形式,其N-氧化物,其药学上可接受的盐或其溶剂合物,以及制备这些化合物的方法,包含所述化合物的药物组合物以及用作 所述化合物的药物。
-
公开(公告)号:US20100190789A1
公开(公告)日:2010-07-29
申请号:US12663013
申请日:2008-06-06
申请人: Jean-Pierre Andre Marc Bongartz , Joannes Theodorus Maria Linders , Lieven Meerpoel , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Mirielle Braeken , Christophe Francis Robert Nestor Buyck , Monique Jenny Marie Berwaer , Katharina Antonia Germania J.M De Waepenaert , Peter Walter Maria Roevens , Gustaaf Maria Boeckx , Peter Vladimirivich Davidenko
发明人: Jean-Pierre Andre Marc Bongartz , Joannes Theodorus Maria Linders , Lieven Meerpoel , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Mirielle Braeken , Christophe Francis Robert Nestor Buyck , Monique Jenny Marie Berwaer , Katharina Antonia Germania J.M De Waepenaert , Peter Walter Maria Roevens , Gustaaf Maria Boeckx , Peter Vladimirivich Davidenko
IPC分类号: A61K31/5377 , C07D241/04 , A61K31/495 , C07D401/12 , A61K31/496 , C07D403/10 , C07D405/12 , C07D403/12 , C07D413/12 , C07D211/34 , A61K31/451 , A61P3/04 , A61P3/06 , A61P3/10 , A61P1/16
CPC分类号: C07D295/205 , C07D207/09 , C07D211/26 , C07D211/38 , C07D213/40 , C07D213/56 , C07D213/61 , C07D213/75 , C07D233/18 , C07D295/192 , C07D295/21 , C07D295/215 , C07D295/24 , C07D295/26 , C07D307/52 , C07D307/79 , C07D309/04 , C07D317/58 , C07D333/24
摘要: The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —C(═O)—; —O—C(═O)—; C(═O)—C(═O)—; —NRx—C(═O)—; —Z1—C(O)—; —Z1—NRx—C(═O)—; —C(═O)—Z1—; —NRx—C(═O)—Z1—; —S(═O)p-; —C(═S)—; —NRx—C(═S)—; —Z1—C(═S)—; —Z1—NRx—C(═S)—; —C(═S)—Z1-; NRx—C(═S)—Z—; Y represents NRx—C(=0)-Z2—; —NRx—C(=0)-Z2—NRy—; —NRx—C(=0)-Z 2—NRy—C(=0)—; —NRx—C(=0)-Z2—NRy—C(=0)-; O—; —NRx—C(=0)-Z2-0-; —NRx—C(=0)-Z2-0-C(=0)-; —NRx—C(=0)-Z2—C(=0)-; —NRx—C(=0)-Z2—C(=0)-; —NRx—C(=0)-0-Z2—C(=0)-; —NRx—C(=0)-0-Z2—C(=0)-0-; —NRx—C(═O)—O—Z2—O—C(═O)—; —NRx—C(═O)—Z2—C(═O)—NRy—; —NRx—C(═O)—Z2—NRy—C(=0)-NRy—; —C(═O)—Z2—; —C(═O)—Z2—O—; —C(=0)-NRx—Z2—; —C(=0)-NRx—Z2-0-; —C(=0)-NRx—Z2—C(=0)-0-; —C(=0)-NRx—Z2-0-C(=0)-; —C(=0)-NRx—Z2—NRy—; —C(=0)—NRx—Z2—NRy—C(=0)-; —C(=0)-NRx—Z2—NRy—C(=0)-0-; R1 represents C1-12alkyl optionally substituted with cyano, C1-4alkyloxy, C1-4alkyl-oxyC1-4alkyloxy, C3-6Cycloalkyl or aryl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; adamantanyl; aryl1; aryl1C1-6alkyl; Het1; or Het1C1-6alkyl; provided that when Y represents —NRx—C(═O)—Z2—; —NRx—C(=0)-Z2—NRy; —NRx—C(═O)—Z2—C(═O)—NRy—; —C(═O)—Z2—; —NRx—C(=0)-Z2—NRy—C(=0)—NRy—; —C(═O)—NR—Z2—; —C(═O)—NR—O—Z2—; or —C(=0)-NRx—Z2—NRy—; then R1 may also represent hydrogen; R2 represents hydrogen, C1-12alkyl, C2-6alkenyl or R3; provided that if X represents —O—C(═O)—; the R2 O represents R3; and provided that (A) is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
-
公开(公告)号:US20100184776A1
公开(公告)日:2010-07-22
申请号:US12663007
申请日:2008-06-05
申请人: Jean-Pierre Andre Marc Bongartz , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Christophe Francis Robert Nestor Buyck
发明人: Jean-Pierre Andre Marc Bongartz , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Christophe Francis Robert Nestor Buyck
IPC分类号: A61K31/496 , C07D241/04 , A61K31/495 , C07D403/12 , A61P3/04 , A61P3/06 , A61P1/16
CPC分类号: C07D295/215 , C07D231/12
摘要: The invention relates to a DGAT inhibitor of formula (I) including any stereochemically isomeric form thereof, wherein A represents CH or N; X represents O or NRx; the dotted line represents an optional bond in case A represents a carbon atom; Y represents a direct bond; —NRx—C(═O)—; —C(═O)—NRx—; —NRx—C(═O)—Z—; —NRx—C(═O)—Z—NRy—; —NRx—C(═O)—Z—NRy—C(═O)—; —NRx—C(═O)—Z—NRy—C(═O)—O—; —NRx—C(═O)—Z—O—; —NRx—C(═O)—Z—O—C(═O)—; —NRx—C(═O)—Z—C(═O)—; —NRx—C(═O)—Z—C(═O)—O—; —NRx—C(═O)—O—Z—C(═O)—; —NRx—C(═O)—O—Z—C(═O)—O—; —NRx—C(═O)—O—Z—O—C(═O)—; —NRx—C(═O)—Z—C(═O)—NRy—; —NRx—C(═O)—Z—NRy—C(═O)—NRy—; —C(═O)—Z—; —C(═O)—Z—O—; —C(═O)—NRx—Z—; —C(═O)—NRx—Z—O—; —C(═O)—NRx—Z—C(═O)—O—; —C(═O)—NRx—Z—O—C(═O)—; —C(═O)—NRx—O—Z—; —C(═O)—NRx—Z—NRy—; —C(═O)—NRx—Z—NRy—C(═O)—; —C(═O)—NRx—Z—NRy—C(═O)—O—; R1 represents optionally substituted C1-12alkyl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; aryl1; aryl1C1-6alkyl; Het1; or Het1C1-6alkyl; provided that when Y represents —NRx—C(═O)—Z—; —NRx—C(═O)—Z—NRy; —NRx—C(═O)—Z—C(═O)—NRy—; —C(═O)—Z—; —NRx—C(═O)—Z—NRy—C(═O)—NRy—; —C(═O)—NRx—Z—; —C(═O)—NRx—O—Z—; or —C(═O)—NRx—Z—NRy—; then R1 may also represent hydrogen; R2 and R3 each independently represent hydrogen; hydroxyl; carboxyl; halo; C1-6alkyl; polyhaloC1-6alkyl; C1-6alkyloxyoptionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; aminocarbonyl; mono- or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono- or di(C1-4alkyl)amino; —S(═O)p-C1-4alkyl; R4 represents hydrogen; hydroxyl; carboxyl; halo; C1-6alkyl; polyhaloC1-6alkyl; optionally substituted C1-6alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted; cyano; C1-6alkylcarbonyl; nitro; amino; mono- or di(C1-4alkyl)amino; C1-4alkylcarbonylamino; —S(═O)p-C1-4alkyl; R6R5N—C(═O)—; R6R5N—C1-6alkyl; C3-6cycloalkyl aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—C1-4alkyl; Het-C(═O)—; Het-O—; R9 represents hydrogen, halo, C1-4alkyl, C1-4alkyl substituted with hydroxyl; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
-
公开(公告)号:US20100210618A1
公开(公告)日:2010-08-19
申请号:US12663011
申请日:2008-06-06
申请人: Jean-Pierre Andre Marc Bongartz , Joannes Theodorus Maria Linders , Lieven Mieerpoel , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Mirielle Braeken , Christophe Francis Robert Nestor Buyck , Monique Jenny Marie Berwaer , Katharina Antonia Germania J.M. De Waepenaret , Peter Walter Maria Roevens , Petr Vladimirivich Davidenko
发明人: Jean-Pierre Andre Marc Bongartz , Joannes Theodorus Maria Linders , Lieven Mieerpoel , Guy Rosalia Eugeen Van Lommen , Erwin Coesemans , Mirielle Braeken , Christophe Francis Robert Nestor Buyck , Monique Jenny Marie Berwaer , Katharina Antonia Germania J.M. De Waepenaret , Peter Walter Maria Roevens , Petr Vladimirivich Davidenko
IPC分类号: A61K31/397 , C07D401/12 , C07D417/12 , A61K31/497 , A61K31/454 , C07D405/12 , C07D241/04 , A61K31/4965 , C07D211/78 , A61K31/451 , C07D403/12 , C07D413/12 , A61K31/5377 , C07D279/02 , A61K31/541 , C07D279/12 , A61P3/04 , A61P3/06 , A61P3/10 , A61P1/16
CPC分类号: A61K31/4523 , A61K31/451 , A61K31/454 , A61K31/495 , A61K31/496 , C07D207/277 , C07D207/323 , C07D211/26 , C07D211/60 , C07D231/12 , C07D233/54 , C07D233/64 , C07D235/18 , C07D249/08 , C07D257/04 , C07D263/34 , C07D277/56 , C07D279/02 , C07D279/12 , C07D295/20 , C07D295/205 , C07D295/21 , C07D295/215 , C07D307/54 , C07D319/18 , C07D401/12 , C07D417/12 , C07D417/14
摘要: The invention relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —O—C(═O)—; —C(═O)—C(═O)—; —NRX—C(═O)—; —Z—C(═O)—; —Z—NRX—C(═O)—; —C(═O)—Z—; —NRX—C(═O)—Z—; —C(═S)—; —NRX—C(═S)—; —Z—C(═S)—; —Z—NRX—C(═S)—; —C(═S)—Z—; —NRX—C(═S)—Z—; Z represents a bivalent radical selected from C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted; and wherein two hydrogen atoms attached to the same carbon atom in C1-6alkanediyl may optionally be replaced by C1-6alkanediyl; Y represents —C(═O)—NRX— or —NRX—C(═O)—; R1 represents adamantanyl, C3-6cycloalkyl; aryl1 or Het1; R2 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl or heterocycle may optionally be substituted; R7 represents hydrogen, halo, C1-4alkyl, C1-4alkyl substituted with hydroxyl; provided that the following compounds (II), (III) are excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine, as a DGAT inhibitor, of said compounds.
-
-
-
-
-
-
-
-
-